#### Title

Placebo and Nocebo Responses in Multiple System Atrophy - a systematic review and meta-analysis of clinical trials

#### **Authors**

Afonso Pessoa de Amorim (1,2), Filipe B Rodrigues (1,2,3), Ana Castro-Caldas (1,2,4), Joaquim J Ferreira (1,2,4)

#### **Affiliations**

- 1 Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- 2 Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal
- 3 UCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK
- 4 CNS Campus Neurológico, Torres Vedras, Portugal

### Corresponding author

Joaquim J Ferreira
Laboratório de Farmacologia Clínica e Terapêutica
Faculdade de Medicina de Lisboa
Av. Prof. Egas Moniz
1649-028 Lisboa
Portugal
Phone + 351 21 7802120
Fax + 351 21 7802129
jferreira@medicina.ulisboa.pt

### **Abstract**

**BACKGROUND:** Multiple System Atrophy (MSA) is a rapidly progressive and fatal neurodegenerative disease, with no effective treatment. Estimating the placebo and nocebo responses will help better design and interpret clinical trials.

**Objective:** To estimate the placebo and nocebo responses in MSA and explore their determinants.

**METHODS:** Electronic databases were searched up to November 2020. Randomized, blinded, placebo- or sham-controlled trials of patients with MSA were included if quantitative data were extractable on the placebo arm. The primary outcomes were: placebo response, defined as the within-group change from baseline, using any scale measuring motor outcomes; and nocebo response, defined as the proportion of patients experiencing adverse effects in the placebo arm. Random-effects meta-analyses were used to pool data. Several predetermined subgroup analyses and metaregressions were performed. PROSPERO registration number: CRD42021222915.

**RESULTS:** We included 21 randomized controlled trials (614 participants). Pooled placebo response was an increase in the Unified MSA Rating Scale (UMSARS) parts I and II of 9.09 points (95% CI 7.78 to 10.31,  $I^2$ =94.00%, 9 studies, 304 participants). Pooled nocebo response was 63,88% (CI 95% 41.15 to 84.05,  $I^2$ =93.03%, 13 studies, 331 participants). Both placebo and nocebo responses were greater in trials with longer duration, whereas nocebo response was also higher in studies testing pharmacological interventions when compared with non-pharmacological interventions.

**CONCLUSIONS:** There may be a favorable response associated with the placebo, but this data needs to be compared with a "no treatment group" in order to validate its real impact. The nocebo response is high and should be considered in future

clinical trial design and interpretation.

# **Supplementary Materials**

## Full Methodology

**Standard protocol approvals and registrations:** We report this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines.<sup>1</sup> The protocol was prospectively registered with PROSPERO (registration: CRD42021222915).

Eligibility criteria: We included randomized controlled trials (RCTs), of parallel or crossover design, double- or single-blinded, studying the effects of therapeutic interventions in people with MSA. We accepted trials that were published or registered with results. All studies had to be placebo or sham controlled. Participants had to be adults (i.e. ≥ 18 years of age) with a clinical diagnosis made by any physician, specialist or otherwise, of MSA. Due to small study bias, studies including less than five participants with MSA were excluded. There were no restrictions regarding the disease state, the number of recruitment centres, language, setting, duration, or year of publication. Studies had to report quantitative data on at least one of the following outcomes, measured by validated instruments, within the placebo arm:

**Primary Efficacy Outcome**: The primary efficacy outcome was "placebo effect response", defined as the within-group change from baseline, using any rating scale measuring the motor domain

**Primary Safety Outcome**: The primary safety outcome was "nocebo effect response", defined as the proportion of patients experiencing adverse effects in the placebo arm.

**Secondary Efficacy Outcomes**: The secondary safety outcomes were within-group change from baseline, using any rating scale measuring the following domains: functional ability, autonomic features, quality of life, and subjective impression of change rated by the patient or clinician.

**Secondary Safety Outcomes**: The secondary safety outcomes were proportion of withdrawals, and proportion of patients experiencing serious adverse effects in the placebo arm.

**Information Sources:** We searched MEDLINE, EMBASE and the Cochrane Register of Controlled Trials (CENTRAL) and FDA's Clinical Trials Database from inception to

November 2020. Searches through reference lists of located trials and of review articles were also conducted to increase the sensitivity of our research strategy.

**Search:** For the identification of studies considered for inclusion, a detailed search strategy was developed for each database searched. All search strategies included Multiple System Atrophy, and database-specific search filters were included to select RCT.<sup>2–4</sup> Below you will find the MEDLINE, CENTRAL and EMBASE strategy.

Selection Process: Two independent reviewers screened the references identified by the search strategy, reading each of the titles and abstracts and excluding references not applicable according to the eligibility criteria. If the abstract was not available for screening, we opted to retrieve the full text of such study. When disagreements arose, they were resolved through discussion or, when necessary, by a third author. Two independent reviewers assessed the full-text articles to see if the studies fulfilled the inclusion criteria. Again, disagreements were resolved through discussion or, if necessary, through the consultation of a third author.

**Data collection process**: Two independent reviewers extracted data to a predetermined and piloted electronic data extraction form. The forms were cross-checked for accuracy.

Risk of bias in individual studies: We used the Cochrane Risk of Bias tool to assess the overall methodological quality of each study<sup>5</sup>. This tool was constructed to incorporate several sources of bias such as selection bias, performance bias, detection bias, attrition bias, reporting bias and other biases. Effectively, we rated a low, unclear or high risk of bias to the seven following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting; to what selective reporting regards, we classified as high risk of bias any study that did not report on all our predefined outcomes, both primary and secondary. As for general risk of bias, we classified as moderate risk a study that did not have all items classified as low risk, and as high risk a study that any item deemed as high risk. Two authors independently assessed each risk of bias domain and disagreements were solved by discussion and, if necessary, by a third author.

**Summary Measures:** For the study of placebo and nocebo responses, we only considered RCTs where the control arm was a placebo intervention. Furthermore,

only the data regarding the placebo arm was collected and analysed. The placebo and nocebo data was derived from the last measured within-group response in the placebo arm. The effect measures chosen for continuous variables were the raw values or the effect size according to the Hedges g corrected for small-sample bias<sup>6,7</sup>, and for dichotomous variables we used the relative frequencies in the form of percentages.

In case of insufficient reported data, we contacted authors as a first approach. In the lack of a positive response, absent mean changes from baseline and SDs were extracted from unpublished material. In some trials, SD was obtained from standard error or confidence intervals (CI). When such values were not reported, imputation methods were applied. If variances or standard errors or standard deviations of mean differences were not available, they were imputed using a change from baseline standard deviation using a correlation coefficient<sup>8,9</sup>. When only a baseline or a final visit measure of dispersion was available but not the corresponding final visit or baseline value, correspondingly, we imputed the missing value as equal to the existing one, and used a conservative correlation coefficient. When necessary, medians and ranges were converted to means and standard deviations according to the methods developed by Hozo et colleagues<sup>10</sup>. For cross-over trials, we included data from the placebo period only. If placebo data was provided by treatment period we only included the first placebo period. If neither of these were available, we excluded the studies from the analyses.

We calculated the allocation ratio for each study dividing the number of patients allocated to placebo by the number of patients allocated to the

Data was combined using random-effects meta-analysis techniques, namely the Dersimonian-Laird (Dersimonian and Laird 1986) model for (inverse-variance) weighted analysis for continuous and categorical variables. Permutational meta-regressions with 1,000 repetitions were used to explore association with continuous and categorical variables (i.e. meta-regression and subgroup analyses). Heterogeneity between results was assessed using the I<sup>2</sup> performed to quantify inconsistency across studies.

We performed the statistical analysis with the statistical package Stata 16.0 (Houston, Texas). All results are presented with a 95% confidence interval (95% CI).

Additional analysis: We performed subgroup analyses for the following areas, independently of the presence or not of significant heterogeneity: publication status; data imputation status; risk of bias; and study design (i.e. parallel versus

cross-over). Meta-regressions were planned according to: year of publication, follow-up duration, allocation ratio, participants' stage and age, and other baseline characteristics. These analyses were exploratory.

## Search Strategies

### **MEDLINE**

- 1 exp Multiple System Atrophy/ (3598)
- 2 MSA.ti,ab.
- 3 (multiple adj3 system\$ adj3 atroph\$).ti,ab.
- 4 (multisystem\$ adj3 atroph\$).ti,ab.
- 5 (striatonigral adj degeneration).ti,ab.
- 6 (shy-drager adj3 syndrome\$).ti,ab.
- 7 (olivopontocerebellar adj3 atroph\$).ti,ab.
- 8 (olivoponto adj3 cerebellar adj3 atroph\$).ti,ab.
- 9 or/1-8
- 10 randomized controlled trial.pt.
- controlled clinical trial.pt.
- 12 randomized.ab.
- 13 placebo.ab.
- 14 clinical trials as topic.sh.
- 15 randomly.ab.
- 16 trial.ti.
- 17 or/10-16
- 18 exp animals/ not humans.sh.
- 19 17 not 18
- 20 and/9,19

#### **Embase**


- 1 exp Shy Drager syndrome/
- 2 MSA.ti,ab.
- 3 (multiple adj3 system\$ adj3 atroph\$).ti,ab.
- 4 (multisystem\$ adj3 atroph\$).ti,ab.
- 5 (striatonigral adj degeneration).ti,ab.
- 6 (shy-drager adj3 syndrome\$).ti,ab.
- 7 (olivopontocerebellar adj3 atroph\$).ti,ab.
- 8 (olivoponto adj3 cerebellar adj3 atroph\$).ti,ab.
- 9 or/1-8
- 10 (random\$ or placebo\$ or single blind\$ or double blind\$ or triple blind\$).ti,ab.
- 11 RETRACTED ARTICLE/
- 12 or/10-11
- 13 (animal\$ not human\$).sh,hw.
- 14 (book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/
- 15 (random sampl\$ or random digit\$ or random effect\$ or random survey or random regression).ti,ab. not exp randomized controlled trial/
- 16 or/13-15
- 17 12 not 16
- 18 and/9,17

#### **CENTRAL**

- #1 MeSH descriptor: [Multiple System Atrophy] explode all trees
- #2 multiple NEAR/3 system\* NEAR/3 atroph\*
- #3 multisystem\* NEAR/3 atroph\*
- #4 striatonigral NEAR/3 degeneration
- #5 shy-drager NEAR/3 syndrome\*
- #6 olivopontocerebellar NEAR/3 atroph\*
- #7 olivoponto NEAR/3 cerebellar NEAR/3 atroph\*
- #8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 in Trials

### **Full Search Results**

**Publications:** The electronic search returned 952 records (274 from CENTRAL, 301 from MEDLINE, 377 from EMBASE, and none from other database sources), resulting in 621 records after all duplicates were removed. Through abstract screening, 565 records were removed, and after the application of inclusion and exclusion criteria to full-texts, 21 publications were included. Figure 1 shows the flowchart of the search. The detailed reason for exclusion for the 24 studies excluded in full-text review can be found below.



Suppl Fig. 1 - Search flowchart.<sup>11</sup>

#### **Trial Characteristics**

**Publications**: A total of 21 studies, 20 publications $^{12-31}$  and 1 clinical trial registration with results $^{32}$ , were included, with 16 studies $^{14-16,18,19,21-27,29,31-33}$  including only MSA patients and  $5^{12,13,17,20,30}$  including MSA and other conditions. All

reports were written in English. A resume table with the study characteristics can be found in Appendix e-4.

**Study Design:** These trials were conducted between 1986 and 2020. Only 12 studies were multicentric  $^{12,16,19,20,22-25,29-32}$ , and of these only 5 were international  $^{12,16,19,20,31}$ , and the remaining 9 were single-center  $^{13-15,17,18,21,26,27,33}$ . All the 21 trials were controlled with placebo  $^{12-14,16,18-27,29-32}$  (18 studies, n=571) or sham  $^{15,17,33}$  (3 studies, n=43) intervention; 6 trials were cross-over  $^{13,14,17,27,29,30}$  (33,3%) and the remaining  $^{12,15,16,18-26,31-33}$  (n=15, 66,7%) had a parallel design. Regarding outcomes, 13 studies  $(61,9\%)^{15-19,21,23,24,27,29-31,33}$  had a primary motor outcome, 5  $(23,8\%)^{12,22,25,26,32}$  had safety and tolerability as their primary outcome and 2  $(9,5\%)^{14,20}$  had autonomic features as their primary outcome; 1 study  $(4,8\%)^{13}$  had cerebellar symptomatology as its primary outcome.

**Study Participants**: The included studies enrolled a total of 1,221 participants, with 614 (50,2%) in the placebo arm. Regarding the participants included in the placebo arm, among those studies which declared such information (19 studies, n=596), 60% were males (n=359). The mean age in the placebo arms varied between 44 years<sup>13</sup> and 71 years<sup>14</sup>. Among the studies which provided a mean baseline evaluation of motor symptoms in total UMSARS score (I + II), the variation was between  $27^{24}$  and  $55^{26}$ .

**Therapeutic Interventions**: The majority of clinical trials studied pharmacological interventions  $^{12-14,16,18-27,29-32}$  (N=18, 85,7%) whereas only 3 trials  $^{15,17,33}$  (14,3%) assessed non-pharmacological studies. (Table 1).

Intervention	Number of Studies (%)
Amantidine <sup>29</sup>	1
AZD3241 <sup>32</sup>	1
Droxidopa <sup>20</sup>	1
Epigallocathechin gallate <sup>23</sup>	1
Growth-Hormone <sup>19</sup>	1
Hydroxytryptophan <sup>30</sup>	1
Inosine 5'-Monophosphate <sup>22</sup>	1
Lithium <sup>26</sup>	1

Mesenchymal Stem Cells <sup>21</sup>	1
Minocycline <sup>16</sup>	1
Octreotide <sup>14</sup>	1
Paroxetin <sup>18</sup>	1
PD01A/PD03A <sup>25</sup>	1
Rasagiline <sup>31</sup>	1
Rifampicin <sup>24</sup>	1
Riluzole <sup>12,27</sup>	2
Repetitive transcranial magnetic stimulation <sup>15,17,28</sup>	3
Vigabatrin <sup>13</sup>	1

Suppl Table 1 - Interventions included in the included studies


**Risk of Bias:** The extent of the methodological detail reported in the trials was not consistent, and several quality indications were not entirely considered in many publications (fig. 1). Only 12 studies<sup>12,16,17,19–26,31</sup> (57,1%) clearly described the process of random sequence generation; no studies were deemed to be at high risk, and 9 studies<sup>13–15,18,27,29,30,32,33</sup> (42,9%) were considered to be at an unclear risk for this criteria.

Regarding the allocation concealment process, only 11 studies  $^{12,16,17,19-24,26,31}$  (52,4%) described an adequate process and therefore were rated as having a low risk of bias, whereas the remaining 10 studies  $^{13-15,18,25,27,29,30,32,33}$  were assessed as having an unclear risk (47,6%).

As for blinding of participants, 20 studies  $^{12-26,29,31-33}$  (95,2%) were deemed as having a low risk of bias; the other study  $^{27}$  (4,8%) failed to provide an adequate blinding, being therefore considered at a high risk of bias; concerning the blinding of outcome assessment, all 21 studies (100%) were considered at a low risk of bias.

Incomplete assessment of outcomes was evaluated to be at a low risk on only 9 trials  $^{14,15,17,20,27,29,30,32,33}$  (42,8%), whereas the remaining had an unclear  $^{21,24}$  (n=2, 9.5%) or high  $^{12,13,16,18,19,22,23,25,26,31}$  (n=10, 47.6%) risk of bias.

Finally, regarding selective outcome reporting data, all the 21 studies (100%) were deemed at a high risk of bias, because none reported all the criteria that we deemed necessary to our evaluation.



**Suppl Fig. 2.** Review author's judgements about each bias, presented as percentages across all studies.<sup>34</sup>

## **Included Trials Characteristics**

Article	Intervention	Trial Design	n total	n placebo	Follow-u	% males	Mean age	Motor scale	Mean motor classification
Bensimon 2008 <sup>12</sup>	Riluzole	Parallel, double-blinded, multicentric and international	404	201	156	54,7%	62,26	Short Motor Disability Scale	6,1
Bonnet 1986 <sup>13</sup>	Vigabatrin	Cross-over, double-blinded and single centric	5	5	16	40%	44		
Bordet 1995 <sup>14</sup>	Ocreotide	Cross-over, double-blinded and single centric	9	9	immediate	33,3%	71		
Chou 2015 <sup>15</sup>	Repetitive Transcranial Magnetic Stimulation	Parallel, double-blinded and single centric	19	10	2	52,6%	55	UMSARS-II	20
Dodel 2009 <sup>16</sup>	Minocycline	Parallel, double-blinded, multicentric and international	63	31	48	46%	62,02	UMSARS-I+II	42,99
França 2020 <sup>17</sup>	Repetitive Transcranial Magnetic Stimulation	Cross-over, double-blinded and single centric	8	8	8	37,5%	61,1	Scale for the Assessment and Rating of Ataxia	14
Friess 2006 <sup>18</sup>	Paroxetine	Parallel, double-blinded and single centric	20	11	2	50%	65,05	UPDRS	27,78
Holmberg 2007 <sup>19</sup>	Growth Hormone	Parallel, double-blinded, multicentric and international	33	21	52	60,5%	60,1	UMSARS-I+II	49,9
Kaufmamn 2014 <sup>20</sup>	Droxidopa	Parallel, double-blinded, multicentric and international	33	11	1				
Lee 2012 <sup>21</sup>	Mesenchymal Stem Cells	Parallel, double-blinded and single centric	33	17	51	63,6%	54,95	UMSARS-I+II	39,79
Lee 2020 <sup>22</sup>	Inosine	Parallel, double-blinded and	55	25	24	54,5%	63,1	UMSARS-I+II	53,28

	5'-Monophosphate	multicentric							
Levin 2019 <sup>23</sup>	Epigallocathechin galate	Parallel, double-blinded and multicentric	92	45	52	59,8%	63,1	UMSARS-I+II	43,01
Low 2014 <sup>24</sup>	Rifampicin	Parallel, double-blinded and multicentric	100	50	52	61%	61	UMSARS-I+II	28,5
Meissner 2020 <sup>25</sup>	PD01A and PD03A	Parallel, double-blinded and multicentric	30	6	52	63,3%	59,	UMSARS-I+II	59,5
Poewe 2015 <sup>31</sup>	Rasagiline	Parallel, double-blinded, multicentric and international	174	90	48	57,5%	65	UMSARS-I+II	37,22
Saccá 2013 <sup>26</sup>	Lithium	Parallel, double-blinded and single centric	9	5	52	77,8%	64	UMSARS-I+II	55
Seppi 2006 <sup>27</sup>	Riluzole	Cross-over, double-blinded and single centric	10	10	12	30%	62	UPDRS-III	38
Song 2020 <sup>33</sup>	Repetitive Transcranial Magnetic Stimulation	Parallel, double-blinded and single centric	50	25	1	58%	53,15	Scale for the Assessment and Rating of Ataxia	18,35
Wenning 2005 <sup>29</sup>	Amantadine	Cross-over, double-blinded and multicentric	8	8	7	75%	64,7	UPDRS-III	35
Wessel 1995 <sup>30</sup>	Hydroxytryptophan	Cross-over, double-blinded and multicentric	7	7	90				
AZD3241 2016 <sup>32</sup>	ADZ3241	Parallel, double-blinded and multicentric	59	19	12	70,7%	59		

# Trials excluded in Full Text Review and reason

Article	Intervention	Reason for exclusion	
Armstrong 1991 <sup>35</sup>	Ocreotide	No information regarding blinding of patients, therefore no assurance that there was any.  Absence of isolated data for the MSA group  Wrong outcome - only measuring reaction and movement time, without using a comparable scales.  Study had the intent of measuring the effect of alcohol ingestion, rather than studying any intervention therapy  Duplicate from another study already included. 15  The study only included 1 patient with MSA, therefore not meeting the minimum number of MSA subjects  Absence of isolated data for the MSA group  Absence of isolated data for the MSA group  Absence of isolated data for the MSA group  Absence of isolated data for the MSA group	
Aschoff 1996 <sup>36</sup>	Physostigmine	Absence of isolated data for the MSA group	
Bier 2003 <sup>37</sup>	Ondaserton	Absence of isolated data for the MSA group	
Botez 1996 <sup>38</sup>	Amantadine Hydrochloride	Wrong outcome - only measuring reaction and movement time, without using any comparable scales.	
Chaudhuri 1994 <sup>39</sup>	Alcohol	l ·	
Chou 2015 <sup>40</sup>	Repetitive Transcranial Magnetic Ressonance	Duplicate from another study already included. <sup>15</sup>	
Fouad-Tar azi 1995 <sup>41</sup>	Midodrine	The study only included 1 patient with MSA, therefore not meeting the minimum number of MSA subjects	
Freeman 1996 <sup>42</sup>	DL-DOPS	Absence of isolated data for the MSA group	
Freeman 1999 <sup>43</sup>	DL-DOPS	Absence of isolated data for the MSA group	
Hussain 2001 <sup>44</sup>	Sildenafil	Absence of isolated data for the MSA group	
Isaacson 2016 <sup>45</sup>	Droxidopa	Absence of isolated data for the MSA group	
Jordan 2002 <sup>46</sup>	СОМТ	No information regarding blinding of patients, therefore no assurance that there was any.	
Jordan 1998 <sup>47</sup>	Multiple vasopressor agents	Absence of data for the placebo group.	
Kaufman 2003 <sup>48</sup>	L-DOPS	Absence of isolated data for the MSA group	


Lee 2008 <sup>49</sup>	Autologous Mesenchymal Stem Cells	Absence of any sort of blinding.
Lipp 2003 <sup>50</sup>	Riluzole	Absence of any sort of blinding.
Mancini 2003 <sup>51</sup>	Botulinum Toxin Type A	Absence of isolated data for the MSA group.
Mullen 2018 <sup>52</sup>	AZD3241	Only abstract available; information duplicated from another study, already included. <sup>32</sup>
Park 2016 <sup>53</sup>	Mesenchymal Stem Cells	Duplicate from another study already included. <sup>21</sup>
Pollak 1987 <sup>54</sup>	Apomorphine and Domperidone	The study only included 2 patients with MSA, therefore not meeting the minimum number of MSA subjects
Singer 2014 <sup>55</sup>	Rifampicin	Duplicate from another study already included. <sup>24</sup>
Singer 2006 <sup>56</sup>	Pyridostigmine	Absence of isolated data for the MSA group.
Sunwoo 2014 <sup>57</sup>	Mesenchymal Stem Cells	Longitudinal non-blinded study.
Wang 2016 <sup>58</sup>	Repetitive Transcranaial Magnetic Stimulation	Duplicate from another study already included. <sup>40</sup>

# **Efficacy Outcomes**


## Subgroup analysis for Primary Efficacy Outcomes

	Placebo Respon Motor Evaluation		I+II	Placebo Response Motor Evaluation - smd			
	Effect Size (95%	p value	12 (%)	Effect Size (95%	p value	12 (%)	
Global Results	80	***	1001				
	9.09 (7.78 to 10.	p<0.001	94.00%	1.04 (0.59 to 1.4	p<0.001	97.3%	
Result Consistency							
Publication Status							
Published	9.64 (8.36 to 10.	p<0.001	94.40%	1.08 (0.60 to 1.5	p<0.001	97.40%	
Unpublished	4.70 (2.32 to 7.0	p<0.001	n/a	0.58 (0.26 to 0.9	p<0.001	n/a	
Difference	5.62 (-6.33 to 17	p=0.329	94.37%	0.60 (-3.85 to 5.0	p=0.714	97.44%	
Data Imputation	72	***				*	
Imputation	n/a	n/a	n/a	n/a	n/a	n/a	
No Imputation	n/a	n/a	n/a	n/a	n/a	n/a	
Difference	n/a	n/a	n/a	n/a	n/a	n/a	
Study Design			***			1	
Follow-Up (weeks)							
Coef	0.22 (0.01 to 0.4	p= 0.020	91,50%	0.01 (-0.02 to 0.3	p=0.449	97.40%	
Cross-over vs Parallel							
Cross-Over	n/a	n/a	n/a	00 (-0.21 to 0.20)	p=0.968	0.00%	
Parallel	n/a	n/a	n/a	87 (0.84 to 1.93)	A CONTRACTOR OF THE PARTY OF TH	97,80%	
Difference	n/a	n/a	n/a	-1.51 (-3.84 to 0.	The second second	97.28%	
Intervention		- Commonweal	The state of the s		**************************************		
Pharmacological	n/a	n/a	n/a	32 (0.81 to 1.84)	p<0.001	97.5%	
Non-Pharmacological	n/a	n/a	n/a	15 (-0.39 to 0.09)		28.4%	
Difference	n/a	n/a	n/a	1.60 (-1.00 to 4.2		97.14%	
International							
International	1 (6.22 to 17.21)	n<0.001	92 70%	84 (0.57 to 3.11)	n=0.005	98.9%	
Non-international	8.35 (6.58 to 10.	-	92.90%	78 (0.29 to 1.26)		95.6%	
Difference	3.09 (-5.36 to 11	p=0.358	92.84%	0.92 (-1.50 to 3.3		97.26%	
Multi-center	1	10		,	1.		
Multi-centric	47 (7.66 to 11.27	n<0.001	94 70%	23 (0.67 to 1.80)	n<0.001	97.7%	
Single-Centric	8.30 (7.92 to 8.6		n/a	61 (-0.08 to 1.29)	-	93.9%	
Difference	1.63 (-11.23 to 1		94.74%	0.31 (-1.90 to 2.5		97.13%	
Year of Publication	1.00 ( 1.00	P .,			11		
Coef	-0.45 (-1.35 to 0.	p=0.181	93.97%	0.05 (-0.10 to 0.2	p=0.465	97.43%	
Allocation Ratio					,		
Coef per % change	0.00 (0.00 to 0.0	p=0.236	94.67%	0.00 (0.00 to 0.0	p=0.752	98.00%	
Population Characteris						0.0000000	
% males							
Coef per % change	0.19 (-0.19 to 0.5	n=0.412	94.52%	0.03 (-0.05 to 0.1	0=0.401	97.52%	
Mean Age (years)	0.10 (-0.10 10 0.1	IP O.TIE	J-1.02 /0	5.55 (-5.55 10 0.	0.401	37.0270	
Coef	0.51 (-0.94 to 1.9	n=0.495	94.72%	0.03 (-0.27 to 0.3	n=0 575	97.29%	
	0.01 (-0.04 10 1.8	10.433	34.7270	0.03 (-0.27 10 0.3	1P-0.073	31.2370	
Mean Motor Scale (units) Coef	-0.19 (-0.79 to 0.	n=0.727	91.14%	-0.05 (-0.34 to 0.	n=0.600	98.61%	
Coei	1-0.19 (-0.79 to 0.	p-0.727	91.1470	-0.05 (-0.34 to 0.	p-0.090	90.0176	

## Forest Plot for Autonomic Function



Forest Plot for Functional Ability



# Safety Outcomes

## Subgroup analysis for Primary and Secondary Safety Outcomes

	Nocebo Response Proportion of Adverse Ef	facte	Nocebo Respons Serious Adverse		ortion	Nocebo Respons Withdrawals pro		
	14.5. a. 1.0.	0.0000000000000000000000000000000000000			12 (%)			12 (%)
Global Results	Percentage (95% p value	12 (70)	Percentage (95%	p value	12 (70)	Percentage (95%	p value	12 (70)
Siobai Results	63.88 (41.15 to 8 p<0.00	1 93.03%	13.80 (5.77 to 24	n<0.001	74.83%	13.32 (7.54 to 20	n<0.001	53.51%
Result Consistency	00.00 (41.10 to qp -5.00	1 00.0070	10.00 (0.11 to 2	IP -0.001	14.00%	10.02 (1.04 to 20	p -0.001	00.0170
Publication Status								
Published	92.96 (38.37 to 8 p<0.00	1 93.61%	14.89 (6.11 to 26	p<0.001	75.94%	12.75 (6.74 to 19	p<0.001	56.33%
Unpublished	73.68 (51.21 to 8 p<0.00		5.26 (0.94 to 24.	-	n/a	21.05 (8.51 to 43	-	n/a
Difference	-12.27 (-97.50 to p=0.76	6 99.60%	10.49 (-26.50 to	p=0.787	89.25%	-9.50 (-40.51 to 2	p=0.689	79.76%
					•		•	
Data Imputation								
Imputation	70.70 (17.63 to 1 p=0.00	1 0.00%	n/a	n/a	n/a	n/a	n/a	n/a
No Imputation	61.81 (35.82 to 8 p<0.00	1 94.06%	n/a	n/a	n/a	n/a	n/a	n/a
Difference	3.33 (-51.52 to 5 p=0.91	99.48%	n/a	n/a	n/a	n/a	n/a	n/a
Study Design								
Follow-Up (weeks)								
Coef	1.40 (0.83 to 1.9 p<0.00	1 86.46%	0.51 (0.37 to 0.6	p<0.001	0.00%	0.27 (0.01 to 0.5	p=0.050	70.32%
	, p-0.00		1		The state of the s			
Cross-over vs Parallel								
Cross-Over	47.73 (26.11 to 6 p<0.00	1 0.00%	n/a	n/a	n/a	1.65 (0.00 to 15.	p=0.506	8.30%
Parallel	(41.47 to 89.10) p<0.00		6 n/a	n/a	n/a	15.23 (8.97 to 22		56.81%
Difference	-16.88 (-73.07 to p=0.52	0 99.61%	n/a	n/a	n/a	-11.91 (-28.06 to		79.91%
Intervention								
Pharmacological	78.60 (64.72 to 9 p<0.00	1 81.12%	19.36 (11.23 to 2	p<0.001	60.33%	17.77 (12.72 to 2	p<0.001	17.36%
Non-Pharmacological	00 (0.00 to 4.90) p=1.00	0.00%	6 00 (0.00 to 4.90)	p=1.000	0.00%	0.00 (0.00 to 4.0	p=1.000	0.00%
Difference	77.63 (47.53 to 1 p=0.01	5 87.60%	18.17 (-3.76 to 4	p=0.140	85.64%	15.54 (2.80 to 28	p=0.033	73.19%
International								
International	78.10 (69.69 to 8 p<0.00	1 61.23%	21.74 (3.37 to 48	0.004	83.02%	23.53 (13.25 to 3	0.004	n/a
Non-international	(30.36 to 85.78) p<0.00			-	66.02%	9.941 (3.82 to 17	-	51.16%
Difference	23.62 (-36.43 to  p=0.36	A CONTRACTOR OF THE PROPERTY O	9.87 (-14.34 to 3		88.85%	15.82 (0.67 to 30		67.46%
Difference	20.02 (-30.43 to   p-0.30	3 33.3370	9.67 (-14.34 10 3	p-0.424	00.0076	10.02 (0.07 to 50	p-0.010	07.4070
Multi-center								
Multi-centric	78.04 (63.19 to 9 p<0.00	1 81.84%	19.36 (11.23 to 2	p<0.001	60.33%	17.79 (11.56 to 2	p<0.001	42.01%
Single-Centric	4 (0.00 to 92.98) p<0.00		6 00 (0.00 to 4.90)			6.73 (0.00 to 19.		52.89%
Difference	35.47 (-5.05 to 7) p=0.13		18.17 (-3.75 to 4		85.64%	8.42 (-4.64 to 21		75.88%
			*		1			
Year of Publication	107			-		76		40
Coef	0.04 (-2.66 to 2.7 p=0.94	9 99.55%	-1.84 (-4.86 to 1.	p=0.281	88.36%	-0.51 (-1.52 to 0.	p=0.344	79.84%
Allocation Ratio								
Coef per % change	-0.01 (-0.03 to 0. p=0.53	0 99.69%	0.01 (-0.01 to 0.0	n=0 322	88.98%	0.00 (0.00 to 0.0	n=0 279	83.59%
occ. par /s criange	0.01 (-0.03 to 0. p=0.53	00.0070	10.01 (-0.01 10 0.0	P 0.022	00.0070	0.00 (0.00 10 0.0	P .0.210	00.0070
Population Characteri	stics							
% males	14 07 / 0 20 /- 0 10 24	0. 540	0.00/0454-4	I0 440	00.048/	0.00 ( 0.50 +- 0	0.757	00.048/
Coef per % change	1.07 (-0.39 to 2.5 p=0.21	3 99.51%	089 (-0.15 to 1.	p=0.113	89.21%	-0.08 (-0.53 to 0.	p=0.757	80.81%
Mean Age (years)								
Coef	2.52 (-1.35 to 6.3 p=0.11	99.01%	2.39 (1.00 to 3.7	p=0.006	53.26%	0.60 (-0.83 to 2.0	p=0.376	77.87%
Mean Motor Scale (units)								
Coef Coef	0.01 (-2.39 to 2.4 p=0.94	0 91.76%	-0.14 (-1.49 to 1.	n=0.758	43.57%	0.78 (-0.22 to 1.7	n=0.160	69.01%
0001	J.U1 (-2.35 to 2.4 p=0.94	0   01.7070	-0.14 (-1.45 to 1.	P-0.700	43.0770	00 (-0.22 10 1.	p-0.100	09.0176

## Bibliography

- Neal R Haddaway, Luke McGuinness. PRISMA2020: R Package and ShinyApp for Producing PRISMA 2020 Compliant Flow Diagrams. Zenodo; 2020. doi:10.5281/ZENODO.4287835
- 2. Glanville JM. How to identify randomized controlled trials in MEDLINE: ten years on. *J Med Libr Assoc*. Published online 2006:7.
- 3. Lefebvre C, Eisinga A, McDonald S, Paul N. Enhancing access to reports of randomized trials published world-wide the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library. *Emerg Themes Epidemiol.* 2008;5(1):13. doi:10.1186/1742-7622-5-13
- 4. Wong; S, Wilczynski; N, Haynes R. Developing optimal search strategies for detecting clinically sound treatment studies. *Med Libr Assoc.* J2006(94(1)):41-47.
- 5. Higgins J, Altman D. Assessing Risk of Bias in Included Studies. In: *Cochrane Handbook for Systematic Reviews of Interventions:*; 2008:187-241.
- 6. Wasserman S, Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. *J Educ Stat.* 1988;13(1):75. doi:10.2307/1164953
- 7. Durlak JA. How to Select, Calculate, and Interpret Effect Sizes. *J Pediatr Psychol*. 2009;34(9):917-928. doi:10.1093/jpepsy/jsp004
- 8. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. *J Clin Epidemiol*. 1992;45(7):769-773. doi:10.1016/0895-4356(92)90054-Q
- Abrams KR, Gillies CL, Lambert PC. Meta-analysis of heterogeneously reported trials assessing change from baseline. Stat Med. 2005;24(24):3823-3844. doi:10.1002/sim.2423
- 10. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol*. 2005;5(1):13. doi:10.1186/1471-2288-5-13
- 11. Neal R Haddaway, Luke McGuinness. *PRISMA2020: R Package and ShinyApp for Producing PRISMA 2020 Compliant Flow Diagrams*. Zenodo; 2020. doi:10.5281/ZENODO.4287835
- 12. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study. *Brain*. 2009;132(1):156-171. doi:10.1093/brain/awn291
- 13. Bonnet AM, Esteguy M, Tell G, Schechter PJ, Hardenberg J, Agid Y. A Controlled Study of Oral Vigabatrin (γ-Vinyl GABA) in Patients with Cerebellar Ataxia. *Can J Neurol Sci J Can Sci Neurol*. 1986;13(4):331-333. doi:10.1017/S0317167100036672
- Bordet R, Benhadjali J, Destée A, Belabbas A, Libersa C. Octreotide Effects on Orthostatic Hypotension in Patients with Multiple System Atrophy: A Controlled Study of Acute Administration. *Clin Neuropharmacol*. 1995;18(1):83-89. doi:10.1097/00002826-199502000-00012
- 15. Chou Y hui, You H, Wang H, et al. Effect of Repetitive Transcranial Magnetic Stimulation on fMRI Resting-State Connectivity in Multiple System Atrophy. *Brain Connect*. 2015;5(7):451-459. doi:10.1089/brain.2014.0325
- Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [ <sup>11</sup> C] (R) -PK11195 PET (MEMSA-trial): Efficacy of Minocycline for Patients with MSA-P. Mov Disord. 2010;25(1):97-107. doi:10.1002/mds.22732
- 17. França C, de Andrade DC, Silva V, et al. Effects of cerebellar transcranial magnetic stimulation on ataxias: A randomized trial. *Parkinsonism Relat Disord*. 2020;80:1-6. doi:10.1016/j.parkreldis.2020.09.001
- 18. Friess E, Kuempfel T, Modell S, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. *Parkinsonism Relat Disord*. 2006;12(7):432-437. doi:10.1016/j.parkreldis.2006.04.002

- 19. Holmberg B, Johansson JO, Poewe W, et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. *Mov Disord*. 2007;22(8):1138-1144. doi:10.1002/mds.21501
- 20. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial. *Neurology*. 2014;83(4):328-335. doi:10.1212/WNL.00000000000015
- 21. Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. *Ann Neurol*. 2012;72(1):32-40. doi:10.1002/ana.23612
- 22. Jung Lee J, Han Yoon J, Jin Kim S, et al. Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study). *Clin Pharmacol Ther*. Published online November 30, 2020:cpt.2082. doi:10.1002/cpt.2082
- 23. Levin J, Maaß S, Schuberth M, et al. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2019;18(8):724-735. doi:10.1016/S1474-4422(19)30141-3
- 24. Low PA, Robertson D, Gilman S, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2014;13(3):268-275. doi:10.1016/S1474-4422(13)70301-6
- 25. Meissner WG, Traon AP, Foubert-Samier A, et al. A Phase 1 Randomized Trial of Specific Active A-Synuclein Immunotherapies PDo<sub>1</sub>A and PDo<sub>3</sub>A in Multiple System Atrophy. *Mov Disord*. 2020;35(11):1957-1965. doi:10.1002/mds.28218
- 26. Saccà F, Marsili A, Quarantelli M, et al. A randomized clinical trial of lithium in multiple system atrophy. *J Neurol*. 2013;260(2):458-461. doi:10.1007/s00415-012-6655-7
- 27. Seppi K, Peralta C, Diem-Zangerl A, et al. Placebo-controlled trial of riluzole in multiple system atrophy. *Eur J Neurol.* 2006;13(10):1146-1148. doi:10.1111/j.1468-1331.2006.01452.x
- 28. Song P, Li S, Wang S, Wei H, Lin H, Wang Y. Repetitive transcranial magnetic stimulation of the cerebellum improves ataxia and cerebello-fronto plasticity in multiple system atrophy: a randomized, double-blind, sham-controlled and TMS-EEG study. *Aging*. 2020;12(20):20611-20622. doi:10.18632/aging.103946
- 29. Wenning GK. Placebo-Controlled Trial of Amantadine in Multiple-System Atrophy: *Clin Neuropharmacol.* 2005;28(5):225-227. doi:10.1097/01.wnf.0000183240.47960.f0
- 30. Wessel K, Hermsdorfer J, Deger K, et al. Double-blind Crossover Study With Levorotatory Form of Hydroxytryptophan in Patients With Degenerative Cerebellar Diseases. *Arch Neurol*. 1995;52(5):451-455. doi:10.1001/archneur.1995.00540290037015
- 31. Poewe W, Seppi K, Fitzer-Attas CJ, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. *Lancet Neurol*. 2015;14(2):145-152. doi:10.1016/S1474-4422(14)70288-1
- 32. AstraZeneca. A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy. clinicaltrials.gov; 2017. Accessed February 11, 2021. https://clinicaltrials.gov/ct2/show/NCT02388295
- 33. Song P, Li S, Wang S, Wei H, Lin H, Wang Y. Repetitive transcranial magnetic stimulation of the cerebellum improves ataxia and cerebello-fronto plasticity in multiple system atrophy: a randomized, double-blind, sham-controlled and TMS-EEG study. *Aging*. 2020;12(20):20611-20622. doi:10.18632/aging.103946
- 34. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods*. 2021;12(1):55-61. doi:10.1002/jrsm.1411
- 35. Armstrong E, Mathias CJ. The effects of the somatostatin analogue, octreotide, on postural hypotension, before and after food ingestion, in primary autonomic failure. *Clin Auton Res.* 1991;1(2):135-140. doi:10.1007/BF01826210
- 36. Aschoff JC, Kailer NA, Walter K. [Physostigmine in treatment of cerebellar ataxia]. *Nervenarzt*. 1996;67(4):311-318.

- 37. Bier JC, Dethy S, Hildebrand J, et al. Effects of the oral form of ondansetron on cerebellar dysfunction. *J Neurol*. 2003;250(6):693-697. doi:10.1007/s00415-003-1061-9
- 38. Botez MI, Botez-Marquard T, Elie R, Pedraza OL, Goyette K, Lalonde R. Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. *J Neurol Neurosurg Psychiatry*. 1996;61(3):259-264. doi:10.1136/jnnp.61.3.259
- 39. Chaudhuri KR, Maule S, Thomaides T, Pavitt D, Mathias CJ. Alcohol ingestion lowers supine blood pressure, causes splanchnic vasodilatation and worsens postural hypotension in primary autonomic failure. *J Neurol*. 1993;241(3):145-152. doi:10.1007/BF00868341
- 40. Chou Y hui, Hickey PT, Sundman M, Song AW, Chen N kuei. Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. *JAMA Neurol*. 2015;72(4):432-440. doi:10.1001/jamaneurol.2014.4380
- 41. Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. *Am J Med*. 1995;99(6):604-610. doi:10.1016/S0002-9343(99)80246-0
- 42. Freeman R, Young J, Landsberg L, Lipsitz L. The treatment of postprandial hypotension in autonomic failure with. :8.
- 43. Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: A randomized, placebo-controlled, crossover trial. *Neurology*. 1999;53(9):2151-2151. doi:10.1212/WNL.53.9.2151
- 44. Hussain IF. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. *J Neurol Neurosurg Psychiatry*. 2001;71(3):371-374. doi:10.1136/jnnp.71.3.371
- 45. Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303). *J Park Dis.* 2016;6(4):751-759. doi:10.3233/JPD-160860
- 46. Jordan J, Lipp A, Tank J, et al. Catechol-O-Methyltransferase and Blood Pressure in Humans. *Circulation*. 2002;106(4):460-465. doi:10.1161/01.CIR.0000022844.50161.3B
- 47. Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. *Am J Med*. 1998;105(2):116-124. doi:10.1016/S0002-9343(98)00193-4
- 48. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine Precursor Therapy in Neurogenic Orthostatic Hypotension. *Circulation*. 2003;108(6):724-728. doi:10.1161/01.CIR.0000083721.49847.D7
- 49. Lee P, Kim J, Bang O, Ahn Y, Joo I, Huh K. Autologous Mesenchymal Stem Cell Therapy Delays the Progression of Neurological Deficits in Patients With Multiple System Atrophy. *Clin Pharmacol Ther*. 2008;83(5):723-730. doi:10.1038/sj.clpt.6100386
- 50. Lipp A, Tank J, Stoffels M, Arnold G, Luft FC, Jordan J. Riluzole and blood pressurein multiple system atrophy. *Clin Auton Res.* 2003;13(4):271-274. doi:10.1007/s10286-003-0100-z
- 51. Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. *Mov Disord*. 2003;18(6):685-688. doi:10.1002/mds.10420
- 52. Abstracts of the 6th international multiple system atrophy congress. *Clin Auton Res.* 2018;28(1):137-160. doi:10.1007/s10286-018-0501-7
- 53. Park HJ, Oh SH, Kim HN, Jung YJ, Lee PH. Mesenchymal stem cells enhance α-synuclein clearance via M2 microglia polarization in experimental and human parkinsonian disorder. *Acta Neuropathol (Berl)*. 2016;132(5):685-701. doi:10.1007/s00401-016-1605-6
- 54. Pollak P, Mallaret M, Gaio JM, Hommel M, Perret J. Blood pressure effects of

- apomorphine and domperidone in parkinsonism. Adv Neurol. 1987;45:263-266.
- 55. Singer W, Cheshire W, Fealey R, et al. Randomized Trial of Rifampicin in MSA: Effect on Autonomic Function (S16.006). *Neurology*. 2014;82(10 Supplement):S16.006.
- 56. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine Treatment Trial in Neurogenic Orthostatic Hypotension. *Arch Neurol*. 2006;63(4):513. doi:10.1001/archneur.63.4.noc50340
- 57. Sunwoo MK, Yun HJ, Song SK, et al. Mesenchymal stem cells can modulate longitudinal changes in cortical thickness and its related cognitive decline in patients with multiple system atrophy. *Front Aging Neurosci.* 2014;6. doi:10.3389/fnagi.2014.00118
- 58. Wang H, Li L, Wu T, et al. Increased cerebellar activation after repetitive transcranial magnetic stimulation over the primary motor cortex in patients with multiple system atrophy. *Ann Transl Med.* 2016;4(6):103-103. doi:10.21037/atm.2016.03.24